PubMed

Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.

Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S; OASIS 5 Investigators.

Ann Intern Med. 2007 Sep 4;147(5):304-10.PMID: 17785485 [PubMed - indexed for MEDLINE]Related articlesFree article

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.

MICHELANGELO OASIS 5 Steering Committee, Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, Budaj A, Joyner C, Chrolavicius S, Fox KA.

Am Heart J. 2005 Dec;150(6):1107.PMID: 16338245 [PubMed - indexed for MEDLINE]Related articles

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.

Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S; OASIS 5 and 6 Investigators.

Circulation. 2008 Nov 11;118(20):2038-46. Epub 2008 Oct 27. Erratum in: Circulation. 2008 Dec 16;118(25):e842. PMID: 18955665 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.

Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afzal R, Chrolavicius S, Fox KA, Yusuf S.

J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51. Epub 2007 Oct 15.PMID: 17964037 [PubMed - indexed for MEDLINE]Related articles

Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.

Joyner CD, Peters RJ, Afzal R, Chrolavicius S, Mehta SR, Fox KA, Granger CB, Franzosi MG, Flather M, Budaj A, Bassand JP, Yusuf S.

Am Heart J. 2009 Mar;157(3):502-8.PMID: 19249421 [PubMed - indexed for MEDLINE]Related articles

Comparison of fondaparinux and enoxaparin in acute coronary syndromes.

Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA.

N Engl J Med. 2006 Apr 6;354(14):1464-76. Epub 2006 Mar 14.PMID: 16537663 [PubMed - indexed for MEDLINE]Related articlesFree article

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators.

JAMA. 2004 Jul 7;292(1):55-64. Erratum in: JAMA. 2004 Sep 8;292(10):1178. Dosage error in article text. PMID: 15238591 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.

Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR.

J Am Coll Cardiol. 2009 Jul 28;54(5):468-76.PMID: 19628124 [PubMed - indexed for MEDLINE]Related articles

A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.

Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U; PENTUA Investigators.

J Am Coll Cardiol. 2004 Jun 16;43(12):2183-90.PMID: 15193678 [PubMed - indexed for MEDLINE]Related articles

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators.

JAMA. 2004 Jul 7;292(1):45-54.PMID: 15238590 [PubMed - indexed for MEDLINE]Related articlesFree article

Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.

Mahaffey KW, Ferguson JJ.

Am Heart J. 2005 Apr;149(4 Suppl):S81-90.PMID: 16124952 [PubMed - indexed for MEDLINE]Related articles

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.

Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, Flather M, Steg PG, Mehta SR, Weintraub W.

Am Heart J. 2009 May;157(5):845-52.PMID: 19376310 [PubMed - indexed for MEDLINE]Related articles

Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.

Karthikeyan G, Mehta SR, Eikelboom JW.

Expert Rev Cardiovasc Ther. 2009 Mar;7(3):241-9.PMID: 19296760 [PubMed - indexed for MEDLINE]Related articles

A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.

Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ.

Am Heart J. 2005 Apr;149(4 Suppl):S91-9.PMID: 16124953 [PubMed - indexed for MEDLINE]Related articles

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM.

JAMA. 2004 Jul 7;292(1):89-96. Review.PMID: 15238596 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.

Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group.

JAMA. 2006 Apr 5;295(13):1519-30. Epub 2006 Mar 14.PMID: 16537725 [PubMed - indexed for MEDLINE]Related articlesFree article

Spotlight on fondaparinux sodium in acute coronary syndromes.

Blick SK, Orman JS, Wagstaff AJ, Scott LJ.

BioDrugs. 2008;22(6):413-5. doi: 10.2165/0063030-200822060-00007. Review.PMID: 18998758 [PubMed - indexed for MEDLINE]Related articles

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.

Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F; ACUTE II Investigators.

Am Heart J. 2002 Sep;144(3):470-7.PMID: 12228784 [PubMed - indexed for MEDLINE]Related articles

Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.

Waksman R, Wolfram RM, Torguson RL, Okubagzi P, Xue Z, Suddath WO, Satler LF, Kent KM.

J Invasive Cardiol. 2006 Aug;18(8):370-5.PMID: 16877786 [PubMed - indexed for MEDLINE]Related articles

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.

Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TIMI 11B Investigators.

Am Heart J. 2003 Jul;146(1):33-41.PMID: 12851605 [PubMed - indexed for MEDLINE]Related articles